Following implementation of the Hemp Farming Act, part of the Agricultural Improvement Act of 2018 (aka, “2018 Farm Bill”), interest in hemp-derived products, especially cannabidiol (CBD), has outpaced the development of a legal pathway for their use. As the industry advocates for the US FDA to issue a regulation for lawful marketing of CBD in food and/or dietary supplements, ToxStrategies has been assisting clients in conducting systematic safety evaluations, including those to support future regulatory submissions. Specific experience includes assessment of CBD manufacturing conditions and toxicological safety that could support future Generally Recognized as Safe (GRAS) and New Dietary Ingredient (NDI) submissions, as well as the safety profile of naturally occurring CBD in hemp food products. ToxStrategies continues to monitor regulatory developments in the area of hemp-derived products and participates in relevant trade associations, such as the Council for Responsible Nutrition (CRN), where Dr. Rayetta Henderson (ToxStrategies Managing Scientist) is a member of the CBD Task Force.